CER Daily Newsfeed

Value Viewpoint: July 18, 2025

(7/18, Kimberly Westrich, LinkedIn) comments “...On Thursday, ICER posted its revised Evidence Report assessing the comparative clinical effectiveness and value of nusinersen, onasemnogene abeparvovec-xioi, and risdiplam for spinal muscular atrophy (SMA), and the comparative clinical effectiveness and value of apitegromab for SMA...On Tuesday, ICER released its Final Evidence Report assessing the comparative clinical effectiveness and value of tolebrutinib for the treatment of secondary progressive multiple sclerosis (SPMS).” Full

New Blueprint Guides Patient-Centered Research for More Equitable Health Care

(7/17, Cameron Santoro, The American Journal of Managed Care) reports “...The Blueprint is intended to drive long-term change in how evidence is generated, evaluated, and applied in health care policy and practice, and it offers a shared foundation for inclusive, multistakeholder collaboration. ‘By centering patient priorities and experiences, we can create more relevant, trustworthy, and equitable evidence to inform health care decisions,’ [Center for Innovation & Value Research chief science officer Rick Chapman, PhD] concluded.” Full

Center for Innovation & Value Research Blueprint Aims to Embed Patient Perspectives Across Healthcare Research and Decision-Making

(7/17, Katie McCool, The Evidence Base) reports “...By providing a common reference point, the Blueprint supports more consistent and inclusive collaboration among stakeholders. According to the Center, it is intended to serve both as a foundational resource and a roadmap for advancing methods and tools in patient-centered value research.” Full

Video: Redefining Value: What Payers Want From Comprehensive MS Treatments

(7/18, Ryan Haumschild, PharmD, MS, MBA, CPEL, Kavita V. Nair, PhD, FAAN, The American Journal of Managed Care) “Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather than applying traditional step therapy protocols that may delay optimal treatment.” View Video

UK: NICE Recommends BeOne’s Brukinsa to Treat Mantle Cell Lymphoma on NHS

(7/18, Emily Kimber, PMLiVE) reports “The National Institute for Health and Care Excellence (NICE) has recommended BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib) to treat certain cases of mantle cell lymphoma (MCL). The health technology assessment agency has recommended that the drug be used on the NHS in England and Wales as a treatment option for adults with relapsed or refractory MCL who have received at least one prior line of therapy.” Full